← Back to Search
Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T
R. Gill, A. Tsao, H. Kindler, W. Richards, S. Armato, R. Francis, D. Gomez, S. Dahlberg, A. Rimner, C. Simone, M. D. de Perrot, G. Blumenthal, A. Adjei, R. Bueno, D. Harpole, M. Hesdorffer, F. Hirsch, H. Pass, E. Yorke, K. Rosenzweig, B. Burt, D. A. Fennell, Wolf Lindwasser, S. Malik, T. Peikert, A. Mansfield, R. Salgia, H. Yang, V. Rusch, A. Nowak
Published 2019 · Medicine
Download PDFAnalyze on Scholarcy
Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma (MPM) are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously and lack of specific recommendations within the radiology community about assessment, reporting and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute (NCI) Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer (IASLC), and the Mesothelioma Applied Research Foundation (MARF). One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of MPM in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting and response assessment within clinical trials.
This paper references
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma
A. Klabatsa (2013)
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
Current trends in radiologic management of malignant pleural mesothelioma.
R. Gill (2009)
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
K. Pinker (2017)
Laparoscopy: An important tool in the staging of malignant pleural mesothelioma
K. Conlon (2006)
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment
P. Lizotte (2016)
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
V. Rusch (2016)
Success of genomic profiling of non–small cell lung cancer biopsies obtained by trans‐thoracic percutaneous needle biopsy
R. Gill (2018)
The role of PET in the surgical management of malignant pleural mesothelioma.
R. Flores (2005)
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy.
J. Alvarez (2005)
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems
Andres Kaalep (2017)
Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy
S. Tsim (2018)
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
A. Tsao (2011)
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma
A. Mansfield (2018)
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
D. Delbeke (2006)
Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34).
F. Giesel (2008)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.
V. Gerbaudo (2011)
OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
A. Nowak (2018)
Interventional radiology of the chest: image-guided percutaneous drainage of pleural effusions, lung abscess, and pneumothorax.
J. Klein (1995)
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
R. Boellaard (2014)
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
MR imaging of benign and malignant pleural disease.
R. Gill (2008)
Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease
Kyuichi Kadota (2014)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
R. Gill (2010)
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
H. S. Elliott (2018)
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.
H. Kindler (2018)
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
R. Gill (2018)
Transthoracic Needle Biopsy: An Overview
J. Klein (1997)
Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma
Z. Labby (2013)
Morphologic and functional imaging of malignant pleural mesothelioma.
M. Yamamuro (2007)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
R. Wahl (2009)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
L. Seymour (2017)
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
J. O (2016)
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients
E. Incerti (2018)
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
S. Armato (2018)
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race.
A. Tsao (2018)
Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.
S. Armato (2015)
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.
J. Coolen (2012)
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma
E. Lopci (2014)
Response evaluation in mesothelioma: Beyond RECIST.
Lin Cheng (2015)